Kura Oncology, Inc. (KURA) earnings
KURA earnings moved a median of +0.39% by the close. Quarterly and annual KURA reports and results, each read against the price at its own news timestamp. Back to the KURA overview →
29 measured KURA earnings events.
Where these KURA earnings landedvs 29 measured KURA earnings reactions
| Middle 50% of KURA earnings reactions | -2.26% to +4.05% |
|---|---|
| Median reaction (to close) | +0.39% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 KURA earnings events with a measured close landed between -2.26% and +4.05%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Kura Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +6.00% | -5.35% | |
| Kura Oncology Reports Second Quarter 2026 Financial Results | Press release | +6.00% | -5.35% | |
| Form 10-Q Kura Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.45% | +5.69% | |
| Kura Oncology Reports First Quarter 2026 Financial Results | Press release | +0.45% | +5.69% | |
| Kura Oncology to Report First Quarter 2026 Financial Results | Press release | -0.54% | -0.54% | |
| Form 10-K Kura Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.39% | +7.31% | |
| Form 10-Q Kura Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.62% | +7.79% | |
| Kura Oncology Reports Third Quarter 2025 Financial Results | Press release | -1.62% | +7.79% | |
| Kura Oncology to Report Third Quarter 2025 Financial Results | Press release | -0.85% | -2.56% | |
| Form 10-Q Kura Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.17% | -2.81% | |
| Kura Oncology Reports Second Quarter 2025 Financial Results | Press release | +0.17% | -2.81% | |
| Kura Oncology to Report Second Quarter 2025 Financial Results | Press release | +0.99% | -2.26% | |
| Form 10-Q Kura Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.93% | +3.85% | |
| Kura Oncology Reports First Quarter 2025 Financial Results | Press release | +1.93% | +3.85% | |
| Kura Oncology to Report First Quarter 2025 Financial Results | Press release | -0.31% | +0.94% | |
| Form 10-K Kura Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.32% | -7.29% | |
| Form 10-Q Kura Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.73% | +5.43% | |
| Kura Oncology Reports Third Quarter 2024 Financial Results | Press release | +1.73% | +5.43% | |
| Kura Oncology to Report Third Quarter 2024 Financial Results | Press release | -1.07% | -0.71% | |
| Form 10-Q Kura Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.10% | -1.20% | |
| Kura Oncology Reports Second Quarter 2024 Financial Results | Press release | -0.10% | -1.20% | |
| Kura Oncology to Report Second Quarter 2024 Financial Results | Press release | +0.44% | -0.59% | |
| Form 10-Q Kura Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.49% | +0.39% | |
| Kura Oncology Reports First Quarter 2024 Financial Results | Press release | +0.49% | +0.39% | |
| Kura Oncology to Report First Quarter 2024 Financial Results | Press release | -0.66% | +4.05% | |
| Form 10-K Kura Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.97% | -1.70% | |
| Form 10-Q Kura Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.57% | +2.85% | |
| Kura Oncology Reports Third Quarter 2023 Financial Results | Press release | +0.57% | +2.85% | |
| Kura Oncology to Report Third Quarter 2023 Financial Results | Press release | -0.38% | -3.77% |
Keep exploring
More KURA: analyst actions → · SEC filings → · KURA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
| Penumbra, Inc. (PEN) | 369 | +0.06% | 60% |
| Arcus Biosciences, Inc. (RCUS) | 368 | -0.09% | 45% |
| Ligand Pharmaceuticals Incorporated (LGND) | 367 | +0.06% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.